ReviewFuture oncology (London, England)2016
Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.
Review in Future oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- MRI-derived T stage predicts nodal positivity on PSMA PET/CT in high-risk primary prostate cancer.Frontiers in nuclear medicine · 2026Article
- Article
- Article
- Radiologic-pathologic correlation of prostatic cancer extracapsular extension (ECE).Insights into imaging · 2023Review
- Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML).Diagnostics (Basel, Switzerland) · 2021Review
- Role of MRI for the detection of prostate cancer.World journal of urology · 2021Review
- A narrative review of pelvic lymph node dissection in prostate cancer.Translational andrology and urology · 2020Review
- Article
- A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification.Therapeutic advances in urology · 2018Article
- Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.Radiology · 2018Article
- 3-T multiparametric MRI characteristics of prostate cancer patients suspicious for biochemical recurrence after primary focal cryosurgery (hemiablation).International urology and nephrology · 2017Article
- Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative.Rambam Maimonides medical journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Accurate risk stratification of prostate cancer is achieved with a number of existing tools to ensure the identification of at-risk patients, characterization of disease aggressiveness, prediction of cancer burden and extrapolation of treatment outcomes for appropriate management of the disease. Statistical tables and nomograms using classic clinicopathological variables have long been the standard of care. However, the introduction of multiparametric MRI, along with fusion-guided targeted prostate biopsy and novel biomarkers, are being assimilated into clinical practice. The majority of studies to date present the outcomes of each in isolation. The current review offers a critical and objective assessment regarding the integration of multiparametric MRI and fusion-guided prostate biopsy with novel biomarkers and predictive nomograms in contemporary clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.